Postmenopausal Hormone Rx Decreases Glaucoma Risk

Sunday, July 19, 2015

Postmenopausal Hormone Rx Decreases Glaucoma Risk

Primary Open Angle Glaucoma (POAG) is the most common type of glaucoma we see at D’Ambrosio Eye Care. Recently an interesting relationship was noted between the risk of glaucoma and taking postmenopausal hormone (PMH) treatment. According to researchers publishing in JAMA Ophthalmology  taking “estrogen only” postmenopausal hormone (PMH) treatment may help reduce the risk for primary open-angle glaucoma (POAG).

Postmenopausal Hormone Therapy & Glaucoma
By reviewing data from 152,163 women 50 years or older the researchers found that 1.9 percent of enrollees developed POAG. Each additional month of use of PMH containing estrogen only was associated with a 0.4 percent reduced risk for POAG whereas each additional month of use of estrogen + progesterone or estrogen + androgen hormones did not affect risk for POAG. This is interesting information and will require further prospective clinical studies to understand fully but may offer some novel treatments for primary open angle glaucoma (POAG), an insidious sight threatening eye diseases and the most common type of glaucoma.

If you or someone you know is concerned about their risk of glaucoma, especially if they are using postmenopausal hormone therapy (PMH), they are encouraged to schedule an eye examination at D’Ambrosio Eye Care by calling us at 800-325-3937, visiting D’Ambrosio Eye Care, Google+ or so that we can help.

D'Ambrosio Eye Care provides eye care for patients throughout greater Boston, central and western Massachusetts with office locations at 479 Old Union Turnpike, Lancaster, Massachusetts 01523, 100 Powder Mill Road, Acton, Massachusetts 01720, 413 Main Street, Athol, Massachusetts 01331 and 74 Main Street, Gardner, Massachusetts 01440.